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Response to Letter to Editor – Diamond T et al., JBMR
The  ASBMR  Task  Force  on  vertebral  augmentation  stands  by  their
recommendations that cast doubt on the clinical importance of vertebral
augmentation procedures, including vertebroplasty, for the treatment of
painful osteoporotic vertebral fractures (1). We also strongly refute bias in
our report.  The ASBMR Task Force commenced late in 2013, two years
prior to the published protocol for the VAPOUR trial (2), and comprised
experts from previously published blinded vertebral augmentation trials,
biomechanics, epidemiology, physical therapy and rehabilitation, exercise,
endocrinology, rheumatology and internal medicine. No member had any
conflict  of  interest.  The  two  ASBMR  Task  Force  reports  (1,3)  both
underwent the normal peer review process by JBMR, but were not sent out
for external consultation prior to review, as is normal practice for ASBMR
Task Force reports. 
While the authors note that their complaint against the recent Cochrane
review (4) has been published on the Cochrane website, they failed to
acknowledge that a detailed response clearly refuting their claims of bias
and misrepresentation of the published data, has also been published (5).
We are not yet privy to their detailed rebuttal that has been accepted for
publication, but we remain unconvinced that their arguments should sway
us from our synthesis of the available evidence. 
The  Cochrane  review  considered  the  totality  of  the  evidence  about
vertebroplasty  by  synthesising  evidence  from all  available  randomised
controlled trials. It included 21 trials; five compared vertebroplasty with
placebo  (541  randomised  participants),  eight  with  usual  care  (1126
randomised  participants),  seven  with  kyphoplasty  (968  randomised
participants)  and  one  compared  vertebroplasty  with  facet  joint
glucocorticoid injection (217 randomised participants). While clinical and
technical  differences existed across many of  the trials,  the decision to
pool the data appears to be vindicated by the consistency of the findings
across the five placebo-controlled trials included, as can be seen by visual
inspection  of  the  forest  plots  that  display  almost  no  statistical
heterogeneity.  Excluding  VAPOUR from these analyses would  not  have
altered any of the ASBMR Task Force’s recommendations. 
As  previously  detailed  (5),  while  VAPOUR found that  the  proportion  of
participants with pain scores <4 out of  10 favoured the vertebroplasty
group  at  all  time  points,  the  point  estimates  of  differences  between
groups with respect to mean pain as measured by the numerical rating
scale (NRS) was only of clinical relevance at 2-3 days and there were no
between-group differences at any other time point.  There were also no
between-group differences in mean pain measured by visual analog scale
(VAS) in the subgroup who completed VAS assessments at 14 days and 6
months.  This  suggests  that  a  slightly  different  cut-off for  improvement
(e.g. a NRS score of ≤4) may have yielded results more consistent with
the  null  effect  demonstrated  in  the  pain  data  analysed  as  continuous
variables. The Cochrane review (4), as well as a published evidence-based
review  of  VAPOUR  (6),  outline  other  potential  biases  that  may  have
resulted in an overestimate of the benefit of vertebroplasty in this trial. 
On well-grounded methodologic principles, the lack of an overall benefit of
vertebroplasty over a placebo procedure indicates that subgroup analyses
must  be  viewed  cautiously.  For  the  procedure  to  be  effective  in  one
subgroup, it follows it must be harmful for another group in order to sum
to a null effect. While Diamond et al. note that VAPOUR included a study
population with symptoms of <6 weeks’ duration, they appear to dismiss
the  evidence  from  the  other  four  placebo-controlled  trials  that  also
included participants with short symptom duration, none of which support
their  assertion  that  symptom duration  is  a  significant  treatment  effect
modifier (7-10). 
Notwithstanding delays in receipt of trial intervention in VERTOS IV, which
included participants with symptom duration of ≤9 weeks, the majority
appear to have had duration of pain for ≤6 weeks (7). The VOPE trial, that
Diamond et al. also appear to dismiss, is published as a PhD thesis and
included 52 participants with symptom duration of ≤8 weeks (8). Neither
trial found a clinically relevant benefit of vertebroplasty over placebo. The
other two placebo-controlled trials (9,  10) included a total  of 57 (27%)
participants  with  pain  duration  ≤6  weeks,  in  whom  the  value  of
vertebroplasty  was  previously  investigated  in  individual  patient  data
meta-analyses (11).  These adequately powered subgroup analyses also
failed to show an advantage for vertebroplasty over placebo. As outlined
in the Cochrane review (4), the 2016 open label trial by Yang et al. (12)
appears to be unregistered and is at high risk of selection, performance
and attrition bias, and therefore its results must be viewed with caution.
In  reaching  consensus  on  our  recommendations  regarding  vertebral
augmentation, the ASBMR Task Force also considered its potential harms.
While we indicate there is uncertainty around the risk estimates of harms
with  vertebroplasty  (1),  clinically  important  harms including  respiratory
failure, cement perforation of the heart, cord compression, osteomyelitis
and  death  have  been  reported.  In  an  audit  of  outcomes  among  850
patients with an average age of 78.9 years who underwent vertebroplasty
or  kyphoplasty  in  2011-2012  identified  from  the  American  College  of
Surgeons National Surgical Quality Improvement Program database, 9.5%
had any adverse event, 6.6% had a serious adverse event, 1.5% died, and
10.8% were readmitted within 30 days of the procedure (13). To put these
data in perspective, the 30-day readmission rate among a large cohort of
patients  (>15,000)  in  a  large  US  multicentre  clinical  registry  who
underwent lumbar spine surgery in 2012 was 4.4% (14). 
The  ASBMR Task Force  report  also  indicated  that  an  increased risk  of
incident  symptomatic  vertebral  fractures  arising  due  to  vertebroplasty
cannot  be  excluded  (1).  Data  from  six  trials  reported  more  incident
symptomatic  vertebral  fractures  arose  in  the  vertebroplasty  group
(48/418) compared with 31/422 in the control group, with an RR of 1.29
(95% CI 0.46 to 3.62). 
After evaluating the totality of the evidence for vertebroplasty, we believe
the  potential  harms  of  vertebroplasty  outweigh  any  potential  benefits.
Similarly  limiting  the procedure  to those with symptoms of  ≤3 weeks,
risks providing an unnecessary and potentially harmful treatment for the
majority  of  patients  whose  symptoms  are  likely  to  improve  quickly
irrespective of  treatment,  consistent with the natural  history of  painful
osteoporotic vertebral fractures. 
We strongly  consider  that  both  clinicians  and patients  should  be  well-
informed before choosing vertebral augmentation and believe our ASBMR
Task Force reports provide this evidence. Efforts should now be directed
towards  identifying  promising  alternative  approaches  for  people  with
painful  osteoporotic  vertebral  fractures,  including bracing and exercise.
We  should  also  ensure  that  such  treatments  are  evaluated  in  high
quality, randomized, placebo-controlled trials  and  be  of  proven  benefit
prior to their introduction into routine clinical care.
.
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